• Blog

COVID-19 Pharma Industry Update from GlobalData

Updated: 2 days ago

4 June


Pipeline Drugs

  • 737 (+8 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70.3% are in discovery or preclinical

Clinical Trials

  • 2,041 clinical trials globally (+17 from last update)

  • 403 clinical trials with chloroquine or hydroxychloroquine (+2 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 598 companies and institutions driving prophylactic and curative innovation (+7 from last update)

Deal-making Activity

  • 166 strategic partnerships (-1 from last update)

  • 50 Licensing agreements (unchanged from last update)

  • 8 M&A (unchanged from last update)

  • 26 financing (unchanged from last update)

Therapeutic Update The 'New England Journal of Medicine' published another hydroxychloroquine study yesterday. In the randomized, double-blind, placebo-controlled study, 719 participants who had a high-risk exposure to people with confirmed COVID-19 were given hydroxychloroquine or a placebo within four days after exposure, and the incidence of illness compatible with COVID-19 was measured within 14 days. There was no significant difference in the incidence of new illness between the hydroxychloroquine and the control group (11.8% vs. 14.3%). More adverse events were described in the treatment group (40.1%) than in the placebo group (16.8%), but none of them were serious. One big caveat of the study is that it was conducted online; symptoms and adverse events were self-reported without seeing a doctor. Furthermore, not all study participants were tested for SARS-CoV-2 infection due to the lack of testing availability. However, this study further dampens the hope that the malaria drug can help prevent COVID-19 infections. Meanwhile, the WHO is resuming the hydroxychloroquine arm of their study that is testing several treatment candidates for COVID-19 after a review of safety concerns that were expressed in the large retrospective hydroxychloroquine 'Lancet' study that garnered criticism on its methodology. 'The Lancet' issued an 'Expression of concern' while study results are being validated by an external commission.

Vaccines Update Five finalists have been chosen to receive support from Operation Warp Speed, the US government's initiative to accelerate COVID-19 vaccine development with the goal to deliver up to 300 million vaccine doses for the US by early 2021. With AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer, the finalists are mostly big pharma companies, Moderna being the only biotech. However, most companies entered partnerships to develop COVID-19 vaccines; Pfizer is partnering with German biotech BioNTech for the development of a mRNA vaccine, AstraZeneca is supporting Oxford University's adenovirus vector vaccine, and Merck acquired Austrian biotech Themis to develop a product based on the measles vaccine, and is also collaborating with the non-profit IAVI to develop a COVID-19 vaccine based on its Ebola vaccine. While Merck and Johnson & Johnson have not started human studies, yet, Moderna and the NIH are planning to enroll 30,000 participants for a Phase III study of mRNA-1273 starting in July. Not included in the final group are Sanofi's recombinant vaccine candidate that will utilize an adjuvant from GSK, Novavax's recombinant nanoparticle vaccine, and Inovio's DNA vaccine. Today, AstraZeneca announced to have reached agreements with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Vaccine Alliance Gavi for the production and distribution of 300 million doses of its COVID-19 vaccine for $750M. Furthermore, a licensing agreement gives the Indian vaccine manufacturer Serum Institute of India the ability to produce one billion doses of the vaccine for low- and middle-income countries. These deals will ensure AstraZeneca’s and Oxford’s vaccine candidate AZD1222 will be accessible around the world and comes among ongoing debates as to which country will get first access to a COVID-19 vaccine. On the other side of the Atlantic Ocean, the European Union is planning to use money from its $2.7B rainy day fund for advance purchases of promising vaccine candidates and to increase vaccine production capacity in Europe. Furthermore, France, Germany, Italy, and the Netherlands formed a 'Vaccine Alliance' to help accelerate vaccine production in Europe and to make sure the continent does not fall behind the US and China, where most of the vaccine research is happening.

Disrupted clinical trials

  • 1,273 clinical trials (unchanged from last update)

  • 973 organizations (industry and academia) are impacted (unchanged from last update)

  • 572 companies are impacted (unchanged from last update) as sponsor, collaborator or CRO

  • 1,378 drugs involved (unchanged from last update)

  • Majority of delays are oncology and CNS with 30% and 17.4% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 173 clinical trials resumed after disruption (+4 from last update)


3 June

Pipeline Drugs

  • 729 (+11 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70% are in discovery or preclinical

Clinical Trials

  • 2,024 clinical trials globally (+22 from last update)

  • 401 clinical trials with chloroquine or hydroxychloroquine (+3 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 591 companies and institutions driving prophylactic and curative innovation (+8 from last update)

Deal-making Activity

  • 167 strategic partnerships (+3 from last update)

  • 50 Licensing agreements (+1 from last update)

  • 8 M&A (unchanged from last update)

  • 26 financing (unchanged from last update)

Therapeutic Update A new study by Houston Methodist Medical Center showed COVID-19 convalescent plasma therapy to be safe and effective for the treatment of COVID-19. Of 25 severe COVID-19 patients receiving plasma from recovered patients, nine showed clinical improvement after 7 days and 19 after 14 days. Interestingly, all study participants also received hydroxychloroquine and azithromycin as additional treatment, and two received Gilead's antiviral remdesivir. Larger, randomized and placebo controlled studies have to confirm the benefits of convalescent plasma therapy and control for efficacy of plasma therapy alone and in combination with hydroxychloroquine and/or remdesivir. Meanwhile, the large retrospective hydroxychloroquine study from the Lancet, published two weeks ago, earned further criticism, with 'The Lancet' issuing an 'Expression of concern' while study results are being validated by an external commission. Gilead's antiviral remdesivir is almost ready to be distributed in India, after receiving 'emergency use with condition for five dose administration' status. Following a licensing agreement between Gilead and several generic drug makers to distribute remdesivir in low- and middle-income countries, Jubilant Pharmaceuticals and Cipla are in the process of discussing pricing and dosing of the antiviral with Indian government officials, before approval can be finalized. Furthermore, remdesivir received approval in Taiwan on Saturday and emergency use approval in South Korea today. Vaccines Update Operation Warp Speed, the US government's initiative to support and accelerate COVID-19 vaccine development has a new beneficiary, according to Patrick Soon-Shiong, the owner of NantKwest and ImmunityBio. Operation Warp Speed is already supporting vaccine candidates from Moderna, Johnson & Johnson, and AstraZeneca, and has a total of 14 companies shortlisted for financial support. NantKwest/ImmunityBio are developing a COVID-19 vaccine based on the adenovirus vector 5 (Ad5), also being used by Oxford University/AstraZeneca and CanSino Biologics. By deleting some genes of the viral vector, ImmunityBio is attempting to mitigate preexisting immunity to the Ad5 virus that has been used in other drugs. Furthermore, not only the genetic sequence of the commonly used SARS-CoV-2 surface spike protein is used as antigen, but also a gene encoding a viral nucleocapsid protein with the goal to boost the human immune response. Animal studies in monkeys are about to begin and human clinical trials are planned to start this month. Disrupted clinical trials

  • 1,273 clinical trials (+3 from last update)

  • 973 organizations (industry and academia) are impacted (+2 from last update)

  • 572 companies are impacted (+1 from last update) as sponsor, collaborator or CRO

  • 1,378 drugs involved (+2 from last update)

  • Majority of delays are oncology and CNS with 30% and 17.4% respectively

  • 30.4% of trials are in Phase III, III/IV or IV

  • 169 clinical trials resumed after disruption (+5 from last update)

2 June


Pipeline Drugs

  • 718 (+12 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70% are in discovery or preclinical

Clinical Trials

  • 2,002 clinical trials globally (+32 from last update)

  • 398 clinical trials with chloroquine or hydroxychloroquine (+1 from last update)

  • 22 clinical trials with remdesivir (+1 from last update)

  • 583 companies and institutions driving prophylactic and curative innovation (+11 from last update)

Deal-making Activity

  • 164 strategic partnerships (+1 from last update)

  • 49 Licensing agreements (unchanged from last update)

  • 8 M&A (unchanged from last update)

  • 26 financing (unchanged from last update)

Therapeutic Update A generic version of Fujifilm Toyama's influenza drug Avigan (favipiravir) has received temporary approval in Russia where it is branded as Avifavir. Avifavir is produced by the Russian Direct Investment Fund (RDIF) and ChemRar Group and 60,000 doses will be provided to Russian hospitals over the coming weeks. Preliminary data of 40 COVID-19 patients showed an improvement in the median viral clearance time from 9 days with standard therapy to 4 days with Avifavir. The study run by the I.M. Sechenov First Moscow State Medical University and other institutes in Russia is ongoing and has the goal to enroll 330 patients. Ongoing clinical trials with Avigan in Japan showed a lack of efficacy in preliminary data, but final results have yet to be published. Favipiravir showed potential to treat COVID-19 in a study in March in moderate patients; currently, there are 43 ongoing and planned clinical trials to test favipiravir's efficacy for the treatment of COVID-19.

Vaccines Update The contract drug manufacturer and vaccine developer Emergent BioSolutions struck a $628M deal with the US government agency BARDA for the production of up to hundreds of millions doses of COVID-19 vaccines through 2021. The contract is an extension of an existing partnership with BARDA and part of the US governments 'Operation Warp Speed'. Vaccine doses of a successful candidate will be produced in Baltimore and the contract also sets aside money to expand viral and non-viral drug fill and finish capacity. This deal solidifies the US governments' ambition to produce hundreds of million of vaccine doses through 2021, though which of the COVID-19 vaccine candidates in development will emerge successful and the timeline for the roll-out of a vaccine remain unclear.

Disrupted clinical trials

  • 1,270 clinical trials (+5 from last update)

  • 971 organizations (industry and academia) are impacted (+3 from last update)

  • 571 companies are impacted (+2 from last update) as sponsor, collaborator or CRO

  • 1,376 drugs involved (-4 from last update)

  • Majority of delays are oncology and CNS with 29.8% and 17.2% respectively

  • 30.6% of trials are in Phase III, III/IV or IV

  • 164 clinical trials resumed after disruption (+1 from last update)


1 June


Pipeline Drugs

  • 706 (+14 from last update) and includes a combination of novel agents, as well as repurposed drugs

  • 70% are in discovery or preclinical

Clinical Trials

  • 1,970 clinical trials globally (+39 from last update)

  • 397 clinical trials with chloroquine or hydroxychloroquine (+7 from last update)

  • 21 clinical trials with remdesivir (unchanged from last update)

  • 572 companies and institutions driving prophylactic and curative innovation (+10 from last update)

Deal-making Activity

  • 163 strategic partnerships (unchanged from last update)

  • 49 Licensing agreements (unchanged from last update)

  • 8 M&A (unchanged from last update)

  • 26 financing (unchanged from last update)

Therapeutic Update Gilead Sciences published preliminary results from another Phase III study of its antiviral remdesivir. Results from the first SIMPLE study showing that a 5-day treatment regimen of remdesivir is as effective as a 10-day treatment were announced a month ago and published last week in the New England Journal of Medicine. The second part of the study compared patients with moderate COVID-19 on the 5-day and 10-day remdesivir regimen with patients who received only standard of care treatment. Patients on the 5-day remdesivir treatment were 65% more likely to clinically improve after 11 days, as compared to the control group, whereas patients on the 10-day remdesivir treatment showed an improvement of 31%, though this result was not significant. However, we'll have to wait for complete study results to see data on other endpoints like mortality and a discussion of the confounding difference in clinical improvement for the duration of remdesivir treatment. While the clinical results for remdesivir so far show modest improvement in time to recovery for moderately ill COVID-19 patients, given the lack of alternatives these data support use of remdesivir in these patients, potentially expanding its use to the majority of patients with significant disease due to the novel coronavirus. Eli Lilly announced the start of a placebo-controlled clinical trial testing its antibody treatment candidate for COVID-19, LY-CoV555, that has been developed in cooperation with AbCellara and the Vaccine Research Center at the National Institute for Allergy and Infectious Diseases (NIAID). The antibody was identified from a blood sample of one of the first recovered US COVID-19 patients and the first trial is set to evaluate tolerability and safety of the treatment. Eli Lilly is ramping up manufacturing and will test other monoclonal antibodies for COVID-19 in the coming months.

Vaccines Update Moderna started dosing of the first patients in a Phase II study of its COVID-19 mRNA vaccine candidate mRNA-1273, as the company announced on Friday. A total of 600 healthy subjects are planned to be enrolled; 300 either 18-55 years old or 55 years of age and older, will receive two shots 28 days apart of either the vaccine candidate or a placebo. As concluded from preliminary data from the Phase I study that showed immunogenicity and good tolerability of the vaccine candidate, 50 µg or 100 µg doses will be used. Moderna is planning to start a Phase III study in July.

Global Health Policy Update Last Friday, US President Trump announced the US’ withdrawal from the World Health Organization (WHO) and redirection of funding to other global health needs. The US contributed $450M to the WHO budget in the last year, the largest donation of all member countries. Trump asked the WHO to initiate reforms across a range of issues, but the announcement on Friday came already 10 days after the request. This move comes among the ongoing global COVID-19 pandemic and the need for global cooperation to develop effective treatment options and vaccines.

Disrupted clinical trials

  • 1,265 clinical trials (+16 from last update)

  • 968 organizations (industry and academia) are impacted (+24 from last update)

  • 569 companies are impacted (+8 from last update) as sponsor, collaborator or CRO

  • 1,380 drugs involved (+12 from last update)

  • Majority of delays are oncology and CNS with 29.9% and 17.4% respectively

  • 30.6% of trials are in Phase III, III/IV or IV

  • 163 clinical trials resumed after disruption (+2 from last update)


27 May


Pipeline Drugs

  • 677 (+13 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 71% are in discovery or preclinical

Clinical Trials

  • 1,869 clinical trials globally (+39 from last update)

  • 385 clinical trials with chloroquine or hydroxychloroquine (+1 from last update)

  • 20 clinical trials with remdesivir (unchanged from last update)

  • 548 companies and institutions driving prophylactic and curative innovation (+9 from last update)

Deal-making Activity

  • 161 strategic partnerships (+6 from last update)

  • 47 Licensing agreements (unchanged from last update)

  • 7 M&A (+1 from last update)

  • 25 financing (unchanged from last update).

Therapeutic Update After the WHO paused chloroquine / hydroxychloroquine studies for the treatment of COVID-19, based on a observational study with more than 96,000 subjects that showed a high incidence of side effects using the anti-malaria drug, today the French government revoked a decree that allowed hospitals to use the drug to treat COVID-19 patients. This comes after France's public health watchdog warned against the use of chloroquine. Although large, randomized, placebo-controlled studies for chloroquine / hydroxychloroquine as a treatment for COVID-19 are still missing, accumulating evidence from observational and retrospective studies make a benefit seem unlikely.

Vaccines Update Maryland-based biotech Novavax started enrolling and dosing the first patients for a Phase I/II trial of its COVID-19 vaccine candidate NVX-CoV2373. The vaccine is based on the company’s recombinant nanoparticle technology and is financially supported by the Coalition for Epidemic Preparedness (CEPI) with up to $384M. The same technology is being utilized for the development of Novavax’s influenza vaccine Nanoflu, which includes a plant-based adjuvant. Nanoflu is targeted at the high-risk population of 65 years and above and showed promising immunogenicity data in a Phase III trial. Furthermore, Novavax announced this morning the acquisition of Praha Vaccines for $167M to expand its manufacturing capacity.

Disrupted clinical trials

  • 1,237 clinical trials (+15 from last update)

  • 908 organizations (industry and academia) are impacted (+12 from last update)

  • 535 companies are impacted (+8 from last update) as sponsor, collaborator or CRO

  • 1,355 drugs involved (+12 from last update)

  • Majority of delays are oncology and CNS with 30.4% and 17.5% respectively

  • 31.2% of trials are in Phase III, III/IV or IV

  • 135 clinical trials resumed after disruption



22 May


Pipeline Drugs

  • 657 (+11 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 71% are in discovery or preclinical

Clinical Trials

  • 1,801 clinical trials globally (+30 from last update)

  • 378 clinical trials with chloroquine or hydroxychloroquine (+6 from last update)

  • 20 clinical trials with remdesivir (unchanged from last update)

  • 532 companies and institutions driving prophylactic and curative innovation (+7 from last update)

Deal-making Activity

  • 155 strategic partnerships (+2 from last update)

  • 47 Licensing agreements (+1 from last update)

  • 6 M&A (unchanged from last update)

  • 24 financing (+1 from last update).

Therapeutic Update A new multinational registry analysis of more than 96,000 SARS-CoV-2 confirmed patients who received hydroxochhloroquine or chloroquine with or without antibiotics such as azithromycin compared to a large control group showed no benefit in treatment with the malaria drug, but rather increased mortality and increased frequency of cardiovascular problems. The study published in 'The Lancet' today further dampens the hope of an easy and inexpensive treatment for COVID-19 patients.

Vaccines Update After AstraZeneca announced it will receive $1B in funding from BARDA for the development of the Oxford University COVID-19 vaccine, today the research institution announced the start of participant enrollment for the next stage of clinical development. The new Phase II/III clinical trial will include a Phase II part with subjects 56 years and older and children ages 5-12 years, while the Phase III part will enroll subjects 18 years and older. More than 10,000 participants will be recruited for this next phase and either receive one or two doses of the Oxford coronavirus vaccine ChAdOx1/AZD1222 or a quadrivalent meningococcal vaccine (MenACWY) as placebo. The BARDA funding specifically included further Phase III clinical trials with 30,000 participants in the US, as well as a pediatric study. The adenovirus vector-based vaccine ChAdOx1 nCoV-19 / AZD1222 is currently in Phase I/II clinical studies. Chinese biotech CanSino is adding a new mRNA vaccine to its COVID-19 pipeline. For that, CanSino will collaborate with the Canadian company Precision NanoSystems, which will provide its proprietary RNA vaccine platform for the development of the mRNA lipid nanoparticle vaccine (mRNA-LNP). CanSino is already testing its adenovirus-based COVID-19 vaccine candidate in China, and is planning clinical trials in North America in cooperation with the National Research Council of Canada (NRC). Other companies developing mRNA vaccines that already started clinical trials are Moderna/NIH and BioNTech/Pfizer, while Curevac and TranslateBio/Sanofi's mRNA vaccine candidates are still preclinical.

Disrupted clinical trials

  • 1,228 clinical trials (+5 from last update)

  • 903 organizations (industry and academia) are impacted (+4 from last update)

  • 526 companies are impacted (+6 from last update) as sponsor, collaborator or CRO

  • 1,340 drugs involved (+7 from last update)

  • Majority of delays are oncology and CNS with 30.4% and 17.5% respectively

  • 31.2% of trials are in Phase III, III/IV or IV


21 May


Pipeline Drugs

  • 646 (+7 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 71% are in discovery or preclinical

Clinical Trials

  • 1,771 clinical trials globally (+21 from last update)

  • 372 clinical trials with chloroquine or hydroxychloroquine (+3 from last update)

  • 20 clinical trials with remdesivir (unchanged from last update)

  • 525 companies and institutions driving prophylactic and curative innovation (+4 from last update)

Deal-making Activity

  • 153 strategic partnerships (+1 from last update)

  • 46 Licensing agreements (+3 from last update)

  • 6 M&A (+1 from last update)

  • 23 financing (unchanged from last update).

Therapeutic Update Gilead Sciences, the producer of the antiviral remdesivir that is currently standard of care for the treatment of COVID-19 in the US, will start charging for its drug once the 1.5 million doses it donated run out. The US Institute for Clinical and Economic Review (ICER) argued remdesivir would be cost-effective at $4,460 per course of treatment with the background of a public health emergency, but Gilead has yet to announce remdesivir's price.

Vaccines Update AstraZeneca is staying in the news, finalizing agreements for 400 million doses of the Oxford University vaccine with the capacity to produce one billion doses for global distribution. To further development, production, and delivery of the vaccine, AstraZeneca received $1B in funding from BARDA that includes a Phase III clinical trial with 30,000 participants. The adenovirus vector-based vaccine ChAdOx1 nCoV-19 initially developed by Oxford University has now been named AZD1222 and is currently in Phase I/II clinical studies. California-based biotech Vaxart announced start of a Phase I clinical trial of their oral recombinant COVID-19 vaccine in early H2, after their lead candidate showed promising results in preclinical studies. The company is already developing a seasonal influenza vaccine with oral route of administration, which could help speed the production and distribution of a vaccine. However, Vaxart has yet to bring an approved oral vaccine to the market.

Disrupted clinical trials

  • 1,223 clinical trials (+9 from last update)

  • 899 organizations (industry and academia) are impacted (+6 from last update)

  • 520 companies are impacted (+4 from last update) as sponsor, collaborator or CRO

  • 1,333 drugs involved (+9 from last update)

  • Majority of delays are oncology and CNS with 30.5% and 17.3% respectively

  • 31.2% of trials are in Phase III, III/IV or IV


19 May


COVID-19 Pharma Bulletin

19 May 2020

The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. No options are currently available in either category but the pipeline is crowded with clinical investigations of novel and existing drugs growing exponentially. Gilead’s remdesivir is the new standard of care and has Emergency Use Authorization in the US; the drug is also approved in Japan for treatment in hospitalized patients. Pipeline Drugs

  • 632 (+5 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 71% are in discovery or preclinical

Clinical Trials

  • 1,722 clinical trials globally (+33 from last update)

  • 363 clinical trials with chloroquine or hydroxychloroquine (+5 from last update)

  • 20 clinical trials with remdesivir (+1 from last update)

  • 514 companies and institutions driving prophylactic and curative innovation (+2 from last update)

Deal-making Activity

  • 147 strategic partnerships (unchanged from last update)

  • 43 Licensing agreements (unchanged from last update)

  • 5 M&A (unchanged from last update)

  • 22 financing (unchanged from last update).

Therapeutic Update Gilead has increased the number of remdesivir doses it will donate to the US government from around 607,000 to 940,000. Depending on how many doses a COVID-19 patient receives, that would be enough to treat additional 30,000 to 50,000 patients. According to European Medicines Agency (EMA) officials, remdesivir is close to a conditional market authorization in Europe, but the EMA is being urged by clinical evidence experts such as Germany’s Institute for Quality and Efficiency and the Cochrane Institute to publish all clinical study data alongside authorization to keep the process transparent.

Vaccines Update British drugmaker AstraZeneca is planning to have 30 million doses of the vaccine it is developing with Oxford University's Jenner Institute ready for the UK market by September and 100 million doses by the end of the year. ChAdOx1 nCoV-19 is a adenovirus vector-based vaccine currently in Phase I clinical trials. This announcement comes after the British government promised $80M in funding for the vaccine and further contributes to the ongoing discussion as to which countries will get access to a COVID-19 vaccine first.

Disrupted clinical trials

  • 1,207 clinical trials (+26 from last update)

  • 883 organizations (industry and academia) are impacted (+15 from last update)

  • 512 companies are impacted (+13 from last update) as sponsor, collaborator or CRO

  • 1,304 drugs involved (+22 from last update)

  • Majority of delays are oncology and CNS with 30.6% and 17.4% respectively

  • 31.2% of trials are in Phase III, III/IV or IV





18 May


Pipeline Drugs

  • 627 (+7 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 71% are in discovery or preclinical

Clinical Trials

  • 1,689 clinical trials globally (+29 from last update)

  • 358 clinical trials with chloroquine or hydroxychloroquine (+4 from last update)

  • 19 clinical trials with remdesivir (unchanged from last update)

  • 512 companies and institutions driving prophylactic and curative innovation (+6 from last update)

Deal-making Activity

  • 147 strategic partnerships (unchanged from last update)

  • 43 Licensing agreements (+1 from last update)

  • 5 M&A (unchanged from last update)

  • 22 financing (unchanged from last update).


Therapeutic Update Sorrento Therapeutics, a biotech based in San Diego, announced on Friday the discovery of an antibody that showed 100% inhibition of SARS-CoV-2 in laboratory tests. STI-1499 was found in a screen of the company's library of human antibodies; of about one billion antibodies screened, 100 were investigated in more detail in collaboration with the University of Texas Medical Branch. Sorrento is planning to develop a antibody cocktail in partnership with Mount Sinai Health System in New York, and Phase I clinical studies are planned for June. Only data collected in human subjects will show how promising STI-1499 will really be in protecting people from COVID-19 infections.

Vaccines Update Moderna released interim data from Phase I trials of its mRNA vaccine on Monday morning, showing that mRNA-1273 elicited immune responses at various doses. In the NIAID run study, participants 18-55 years of age received two doses of either 25 µg or 100 µg or one 250 µg dose of the vaccine. After 15 days, participants across all doses showed seroconversion, meaning the body produced antibodies against the viral antigen. After 43 days, the level of antibodies in the 25 µg group matched the level of people who recovered from COVID-19 and significantly exceeded that level in the 100 µg group. Moderna says its vaccine was generally safe and well tolerated, but some adverse events were observed in the 250 µg group. Based on the data, Moderna will continue with 50 µg and 100 µg doses for Phase II clinical trials. The released interim data was only from eight subjects, but the promising immunogenicity results raise optimism on Moderna's ambitious timeline. Moncef Slaoui, new head of the US vaccine initiative ‘Operation Warp Speed', was officially introduced at a White House Rose Garden event on Friday, and assured his confidence in the program's goal to deliver a vaccine by the end of the year. Slaoui is the former head of GlaxoSmithKline's vaccine division and used to be a member of Moderna's board, from which he resigned after joining 'Operation Warp Speed'. The public-private partnership will focus on COVID-19 vaccine development, manufacturing, and distribution, with the aim to produce up to 300 million doses for the US by early next year.

Disrupted clinical trials

  • 1,181 clinical trials (+22 from last update)

  • 868 organizations (industry and academia) are impacted (+20 from last update)

  • 499 companies are impacted (+15 from last update) as sponsor, collaborator or CRO

  • 1,282 drugs involved (+10 from last update)

  • Majority of delays are oncology and CNS with 30.3% and 17.6% respectively

  • 31.1% of trials are in Phase III, III/IV or IV



14 May


Pipeline Drugs

  • 611 (+4 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 72% are in discovery or preclinical

Clinical Trials

  • 1,634 clinical trials globally (+13 from last update)

  • 347 clinical trials with chloroquine or hydroxychloroquine (+3 from last update)

  • 18 clinical trials with remdesivir (unchanged from last update)

  • 500 companies and institutions driving prophylactic and curative innovation(+3 from last update)

Deal-making Activity

  • 147 strategic partnerships (+2 from last update)

  • 42 Licensing agreements (+3 from last update)

  • 5 M&A (unchanged from last update)

  • 22 financing (+1 from last update).

Regulatory Update The World Health Assembly, the decision-making body of the WHO that meets once a year in Geneva, Switzerland, drafted a resolution that leaves room for creating a voluntary pool to collect patent rights for COVID-19 therapeutics, vaccines, and diagnostics. In theory that could mean countries could make use of compulsory licensing, copying a patent from a company without consent from the patent holder, an action that is allowed under a World Trade Organization agreement. However, if countries with big markets will actually make use of that agreement is unclear, since that might disincentivize companies from costly and risky drug development in general and from bringing their products to that particular market.

Disrupted clinical trials

  • 1,139 clinical trials (+18 from last update)

  • 838 organizations (industry and academia) are impacted (+17 from last update)

  • 475 companies are impacted (+24 from last update) as sponsor, collaborator or CRO

  • 1,255 drugs involved (+3 from last update)

  • Majority of delays are oncology and CNS with 31% and 17.5% respectively 30.7% of trials are in Phase III, III/IV or IV


12 May


The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. No options are currently available in either category but the pipeline is crowded with clinical investigations of novel and existing drugs growing exponentially. Gilead’s remdesivir is the new standard of care and has Emergency Use Authorization in the US; the drug is also approved in Japan for treatment in hospitalized patients. Pipeline Drugs

  • 592 (+7 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 72% are in discovery or pre-clinical

Clinical Trials

  • 1,597 clinical trials globally (+38 from last update)

  • 338 clinical trials with chloroquine or hydroxychloroquine (+9 from last update)

  • 18 clinical trials with remdesivir (-4 from last update)

  • 489 companies and institutions driving prophylactic and curative innovation(+3 from last update)

Deal-making Activity

  • 143 strategic partnerships (+1 from last update)

  • 36 Licensing agreements (unchanged from last update)

  • 5 M&A (unchanged from last update)

  • 20 financing (unchanged from last update).

Therapeutic Update The European Medicines Agency (EMA) announced that the agency is expanding remdesivir's compassionate use recommendation. In addition to patients on mechanical ventilation, remdesivir will be recommended for hospitalized patients who require other forms of breathing support such as non-invasive ventilation, supplemental oxygen or high-flow oxygen devices that deliver oxygen via mask or nasal cannula, as well as extracorporeal membrane oxygenation (ECMO), a machine that is connected to the blood circulation system and add oxygen while removing carbon dioxide outside of the body. This expansion from the EMA is in the context of EMA's rolling review of remdesivir, meaning that data for the approval of a new drug is being evaluated as it is published, instead of reviewing data all at once for a new drug approval. A new retrospective cohort study of hydroxychloroquine with or without the antibiotic azithromycin published in JAMA on Monday showed no improvement in in-hospital mortality. In the study, a random sample of COVID-19 patients hospitalized in metro New York City was taken and these 1438 patients were split up in four groups, those receiving hydroxychloroquine or azithromycin alone, a combination of both, or neither. No significant differences in in-hospital mortality were found. This adds to compounding evidence that chloroquine or hydroxychloroquine, with or without azithromycin, is ineffective in treating COVID-19.

Vaccines Update Moderna's COVID-19 vaccine mRNA-1273, developed in collaboration with the NIH, received the FDA's Fast Track designation, as Moderna announced in a press release on Tuesday. This ensures an expedited review of Moderna's regulatory submission, including applications for the start of clinical trials and review of data. Moderna's vaccine candidate is being prepared to start Phase II clinical trials shortly after getting a green light from the FDA last week, and a Phase III study is planned to start in early summer. This is the first vaccine to receive such a designation in the fight against COVID-19, helping Moderna stand out from a continuously growing group of vaccine developers. Novavax, who develop vaccines using virus-like particle (VLP) technology, today announced that the Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $384 million of funding towards clinical development of NVX-CoV2373, Novavax’ candidate vaccine against SARS-CoV-2. The will support both rapid scale-up of the NVX-CoV2373 vaccine antigen, as well as Novavax’ proprietary adjuvant, which aims to enhance immune responses by stimulating high levels of neutralizing antibodies. Additionally, this funding will allow Novavax to develop large-scale manufacturing capacity for both antigen and adjuvant. While no efficacy data are available, this significant financial commitment suggests strong confidence from the CEPI for Novavax' candidate.

Disrupted clinical trials

  • 1,101 clinical trials (+17 from last update)

  • 810 organizations (industry and academia) are impacted (+11 from last update)

  • 451 companies are impacted (+10 from last update) as sponsor, collaborator or CRO

  • 1,234 drugs involved (+33 from last update)

Majority of delays are oncology and CNS with 31.4% and 17.7% respectively

30.7% of trials are in Phase III, III/IV or IV


11 May


Pipeline Drugs

  • 585 (+13 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 72% are in discovery or pre-clinical

Clinical Trials

  • 1,559 clinical trials globally (+70 from last update)

  • 329 clinical trials with chloroquine or hydroxychloroquine (+11 from last update)

  • 22 clinical trials with remdesivir (unchanged from last update)

  • 486 companies and institutions driving prophylactic and curative innovation(+11 from last update)

Deal-making Activity

  • 142 strategic partnerships (+3 from last update)

  • 36 Licensing agreements (+1 from last update)

  • 5 M&A (unchanged from last update)

  • 20 financing (unchanged from last update).

Disrupted clinical trials

  • 1,084 clinical trials (+50 from last update)

  • 799 organizations (industry and academia) are impacted (+39 from last update)

  • 441 companies are impacted (+33 from last update) as sponsor, collaborator or CRO

  • 1,201 drugs involved (+50 from last update)

Majority of delays are oncology and CNS with ~31.5% and 18% respectively

~31% of trials are in Phase III, III/IV or IV


6 May


The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. No options are currently available in either category but the pipeline is crowded with clinical investigations of novel and existing drugs growing exponentially. COVID-19 therapeutics and vaccines are being developed independently and through partnerships between public and private sectors. Pipeline Drugs

  • 555 (+7 from last update) and includes a combination of novel agents, as well as repurposed drugs.

  • 73.5% are in discovery or pre-clinical

Clinical Trials

  • 1,421 clinical trials globally (+24 from last update)

  • 310 clinical trials with chloroquine or hydroxychloroquine (+4 from last update)

  • 21 clinical trials with remdesivir (+1 from last update)

  • 463 companies and institutions driving prophylactic and curative innovation (+7 from last update)

Deal-making Activity

  • 165 stratgegic partnerships (+3 from last update)

  • 5 M&A (+1 from last update)

  • 20 financing (unchanged from last update).

Disrupted clinical trials

  • 1,001 clinical trials (+49 from last update)

  • 743 companies impacted (+29 from last update) as sponsor, collaborator or CRO

  • 1,125 drugs involved

  • 6,940 trial sites across the globe

  • Majority of delays are oncology and CNS with 31% and 18% respectively


5 May


The number of drugs in development has now risen to 548 (+4 from Friday) and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,397 (+35 from Friday) clinical trials for COVID-19 and 456 (+3 from Friday) companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 162 (unchanged from Friday). The nearest solutions on the horizon are antivirals such as Gilead's remdesivir, which got a much needed boost this week, but older drugs such as chloroquine and hydroxychloroquine continue to be touted as potential “game changers.” The number of clinical trials in which chloroquine or hydroxychloroquine are used as a primary or secondary intervention either alone or in combination with other drugs is currently 306 (+14 from Friday) compared to 20 (unchanged from Friday) for remdesivir.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 952 trials delayed (+32 from Friday). The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 714 companies (+17 from Friday) running these clinical trials as either the sponsor, collaborator or CROs. At the beginning of the pandemic, drug supply chains, particularly for companies that have facilities in China, were impacted. The good news is that we are starting to see operations resume in areas such as Wuhan so supply chains are being restored. Newly approved drugs are also experiencing delayed launches; the most recent is Neurocrine's Ongentys (opicapone) for Parkinson's Disease, which received FDA approval on April 28th but will not launch until later this year.​



30 April


The number of drugs in development has now risen to 533 (+23 from yesterday) and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,340 (+33 from yesterday) clinical trials for COVID-19 and 445 (+19 from yesterday) companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 158 (+2 from yesterday). The nearest solutions on the horizon are antivirals such as Gilead's remdesivir, which got a much needed boost yesterday, but older drugs such as chloroquine and hydroxychloroquine continue to be touted as potential “game changers.” The number of clinical trials in which chloroquine or hydroxychloroquine are used as a primary or secondary intervention either alone or in combination with other drugs is currently 285 (+9 from yesterday) compared to 20 (+1 from yesterday) for remdesivir.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 901 trials delayed (+38 from yesterday). The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 667 companies (+11 from yesterday) running these clinical trials as either the sponsor, collaborator or CROs.



29 April




28 April


The number of drugs in development has now risen to 500 and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,271 clinical trials for COVID-19 and 419 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 152.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 863 trials delayed as of this morning. The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 638 companies running these clinical trials as either the sponsor, collaborator or CROs. At the beginning of the pandemic, drug supply chains, particularly for companies that have facilities in China, were impacted. The good news is that we are starting to see operations resume in areas such as Wuhan so supply chains are being restored.


27 April


The number of drugs in development has now risen to 495 and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,227 clinical trials for COVID-19 and 410 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 151.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 835 trials delayed as of this morning. The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 616 companies running these clinical trials as either the sponsor, collaborator or CROs. At the beginning of the pandemic, drug supply chains, particularly for companies that have facilities in China, were impacted. The good news is that we are starting to see operations resume in areas such as Wuhan so supply chains are being restored.


24 April


The number of drugs in development has now risen to 464 and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,135 clinical trials for COVID-19 and 388 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 141.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 795 trials delayed as of this morning. The majority of the delays are due to suspended enrollment followed by delayed initiation of a planned trial. There are 593 companies running these clinical trials as either the sponsor, collaborator or CROs.


23 April


The number of drugs in development has now risen to 441 and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,091 clinical trials for COVID-19 and 369 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 138.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 693 trials delayed as of this morning. The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 546 companies running these clinical trials as either the sponsor, collaborator or CROs.


22 April


The number of drugs in development has now risen to 424 and includes a combination of novel agents, as well as repurposed drugs. Currently there are 1,033 clinical trials for COVID-19 and 356 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 136.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 660 trials delayed as of this morning. The majority of the delays are due to suspended enrollment followed by delayed initiation of a planned trial. There are 529 companies running these clinical trials as either the sponsor, collaborator or CROs


20 April


The number of drugs in development has now risen to 397 and includes a combination of novel agents, as well as re-purposed drugs. Currently there are 960 clinical trials for COVID-19 and 345 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 132.


While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 627 trials delayed as of this morning. The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 505 companies running these clinical trials as either the sponsor, collaborator or CROs.



16 April


The number of drugs in development has now risen to 370 and includes a combination of novel agents, as well as re-purposed drugs. Currently there are 908 clinical trials for COVID-19 and 313 companies and institutions driving prophylactic and curative innovation. The number of Strategic Partnerships now stands at 123.

Even though the first vaccine for COVID-19 will take at least a year to develop, an effective therapy for COVID-19 could be available within a matter of months, as off-the-shelf solutions may already be available and ready for clinical trials. Assuming rapid trial initiation, these trials could produce readouts in a matter of weeks. Data are already available for multiple candidate therapies, including chloroquine/hydroxychloroquine, ritonavir + lopinavir, remdesivir, and favipiravir, among others. Notably, these data have been produced less than five months after the discovery of the virus, demonstrating that short studies for COVID-19 treatments can indeed be completed quite rapidly, although the data are less clear than desired. In a recent poll of visitors to GlobalData’s Pharmaceutical Technology site (n=477), 80% of respondents expressed some level of confidence that an effective treatment for COVID-19 will be available within the next 12 months.

While trials for COVID-19 are progressing, clinical trials in other areas continue to be delayed with at least 595 trials delayed as of this morning. The majority of the delays are due to suspended enrolment followed by delayed initiation of a planned trial. There are 328 companies running these clinical trials as either the sponsor, collaborator or CROs. Oncology is the therapy area with the highest number of disrupted clinical trials, followed by Central Nervous System and Gastrointestinal.



14 April


The eruption of the COVID-19 pandemic has propelled the pharmaceutical industry into action, with a race to develop both preventive and therapeutic interventions. Both an antiviral for disease treatment and symptom relief, as well as a vaccine to prevent transmission, are urgently needed. The number of drugs in development has now risen to 350 and includes a combination of novel agents as well as re-purposed drugs. There are also 296 companies and institutions driving prophylactic and curative innovation.


The number of Strategic Partnerships now stands at 117. In an unprecedented move, two of the largest vaccines companies, Sanofi and GSK, announced this morning that the two companies were joining forces to develop an adjuvanted vaccine for COVID-19. The vaccine candidate will leverage Sanofi’s S-protein SARS-CoV-2 antigen, which is based on recombinant DNA technology along with GSK’s "proven pandemic adjuvant technology". The use of adjuvant technology is particularly important because it could reduce the amount of vaccine protein required per dose, meaning that more vaccine doses can be produced quickly and ultimately more people can be vaccinated. The companies plan to begin a phase I study in the second half of 2020.


In the meanwhile, the upward trends in clinical trial delays continues with at least 557 trials delayed as of this morning. The FDA has also suspended inspection of foreign manufacturing plants and Advisory Committee Meetings have been cancelled or postponed. Both of these recent developments do not bode well for timely regulatory approvals of branded and generic drugs. In a recent GlobalData poll, about 75% and 80% of respondents expressed some level of concern about clinical trial or regulatory delays respectively due to the coronavirus outbreak.


9 April 2020


The pharmaceutical industry is in a race to develop both preventive and therapeutic interventions. Both an antiviral for disease treatment and symptom relief, as well as a vaccine to prevent transmission, are urgently needed. The number of drugs in development has now risen to 305 and includes a combination of novel agents as well as re-purposed drugs. There are also 260 companies and institutions driving prophylactic and curative innovation.


There is an upward trends in clinical trial delays continues with at least 410 trials delayed as of yesterday. Clinical trials irrespective of indication will likely be impacted, not just in terms of recruitment and immediate patient care but also in terms of data collection and analysis in the months to come. The FDA has also suspended inspection of foreign manufacturing plants and Advisory Committee Meetings have been cancelled or postponed. Both of these recent developments do not bode well for timely regulatory approvals of branded and generic drugs.


Source: GlobalData. Information reproduced with the kind permission of GlobalData. All rights reserved by GlobalData. www.globaldata.com


Triumph Research Intelligence Limited

The Bradfield Centre

Cambridge Science Park

Cambridge

CB4 0GA

United Kingdom

  • LinkedIn Social Icon
  • Twitter Social Icon
  • YouTube